405 related articles for article (PubMed ID: 23122646)
1. [Questions--answers on the use of rivaroxaban for the treatment of venous thromboembolic disease].
Pernod G; Elias A; Gouin I; Gaillard C; Nguyen P; Ouvry P; Sié P
J Mal Vasc; 2012 Dec; 37(6):300-10. PubMed ID: 23122646
[TBL] [Abstract][Full Text] [Related]
2. Oral rivaroxaban for symptomatic venous thromboembolism.
; Bauersachs R; Berkowitz SD; Brenner B; Buller HR; Decousus H; Gallus AS; Lensing AW; Misselwitz F; Prins MH; Raskob GE; Segers A; Verhamme P; Wells P; Agnelli G; Bounameaux H; Cohen A; Davidson BL; Piovella F; Schellong S
N Engl J Med; 2010 Dec; 363(26):2499-510. PubMed ID: 21128814
[TBL] [Abstract][Full Text] [Related]
3. Rivaroxaban: a review of its use in the treatment of deep vein thrombosis or pulmonary embolism and the prevention of recurrent venous thromboembolism.
Burness CB; Perry CM
Drugs; 2014 Feb; 74(2):243-62. PubMed ID: 24430916
[TBL] [Abstract][Full Text] [Related]
4. The use of rivaroxaban for short- and long-term treatment of venous thromboembolism.
Cohen AT; Dobromirski M
Thromb Haemost; 2012 Jun; 107(6):1035-43. PubMed ID: 22371186
[TBL] [Abstract][Full Text] [Related]
5. Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (EINSTEIN-extension study).
Romualdi E; Donadini MP; Ageno W
Expert Rev Cardiovasc Ther; 2011 Jul; 9(7):841-4. PubMed ID: 21809964
[TBL] [Abstract][Full Text] [Related]
6. Rivaroxaban for treatment of venous thromboembolism in older adults.
Mitchell AP; Conway SE
Consult Pharm; 2014 Sep; 29(9):627-30. PubMed ID: 25203412
[TBL] [Abstract][Full Text] [Related]
7. Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor.
Turpie AG; Kreutz R; Llau J; Norrving B; Haas S
Thromb Haemost; 2012 Nov; 108(5):876-86. PubMed ID: 23014816
[TBL] [Abstract][Full Text] [Related]
8. [Therapy of pulmonary embolism. Rivaroxaban is superior to standard therapy].
Einecke D
MMW Fortschr Med; 2012 Apr; 154(7):24. PubMed ID: 22558862
[No Abstract] [Full Text] [Related]
9. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Lassen MR; Ageno W; Borris LC; Lieberman JR; Rosencher N; Bandel TJ; Misselwitz F; Turpie AG;
N Engl J Med; 2008 Jun; 358(26):2776-86. PubMed ID: 18579812
[TBL] [Abstract][Full Text] [Related]
10. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study.
Agnelli G; Gallus A; Goldhaber SZ; Haas S; Huisman MV; Hull RD; Kakkar AK; Misselwitz F; Schellong S;
Circulation; 2007 Jul; 116(2):180-7. PubMed ID: 17576867
[TBL] [Abstract][Full Text] [Related]
11. A cost-analysis model for anticoagulant treatment in the hospital setting.
Mody SH; Huynh L; Zhuo DY; Tran KN; Lefebvre P; Bookhart B
J Med Econ; 2014 Jul; 17(7):492-8. PubMed ID: 24773068
[TBL] [Abstract][Full Text] [Related]
12. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
Eriksson BI; Borris LC; Friedman RJ; Haas S; Huisman MV; Kakkar AK; Bandel TJ; Beckmann H; Muehlhofer E; Misselwitz F; Geerts W;
N Engl J Med; 2008 Jun; 358(26):2765-75. PubMed ID: 18579811
[TBL] [Abstract][Full Text] [Related]
13. Venous thromboembolism: EINSTEIN transforms anticoagulant therapy in acute PE.
Kline JA; Yealy DM
Nat Rev Cardiol; 2012 May; 9(7):378-80. PubMed ID: 22566060
[No Abstract] [Full Text] [Related]
14. Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism.
van Bellen B; Bamber L; Correa de Carvalho F; Prins M; Wang M; Lensing AW
Curr Med Res Opin; 2014 May; 30(5):829-37. PubMed ID: 24432872
[TBL] [Abstract][Full Text] [Related]
15. Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program.
Bookhart BK; Haskell L; Bamber L; Wang M; Schein J; Mody SH
J Med Econ; 2014 Oct; 17(10):691-5. PubMed ID: 25065536
[TBL] [Abstract][Full Text] [Related]
16. Rivaroxaban for thromboprophylaxis.
Lotke PA
N Engl J Med; 2008 Nov; 359(20):2174; author reply 2175-6. PubMed ID: 19009675
[No Abstract] [Full Text] [Related]
17. Oral direct factor Xa inhibitors, with special emphasis on rivaroxaban.
Mousa SA
Methods Mol Biol; 2010; 663():181-201. PubMed ID: 20617418
[TBL] [Abstract][Full Text] [Related]
18. Practical management of rivaroxaban for the treatment of venous thromboembolism.
Imberti D; Benedetti R
Clin Appl Thromb Hemost; 2015 May; 21(4):309-18. PubMed ID: 24057396
[TBL] [Abstract][Full Text] [Related]
19. Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban.
Morell J; Sullivan B; Khalabuda M; McBride BF
J Clin Pharmacol; 2010 Sep; 50(9):986-1000. PubMed ID: 20124518
[TBL] [Abstract][Full Text] [Related]
20. Rivaroxaban, the first oral, direct factor Xa inhibitor.
Fassiadis N
Expert Opin Pharmacother; 2009 Dec; 10(18):2945-6. PubMed ID: 19925048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
